Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, Y. H.
Right arrow Articles by Ochiai, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, Y. H.
Right arrow Articles by Ochiai, A.
Clinical Cancer Research Vol. 10, 7311-7317, November 1, 2004
© 2004 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung

Young Hak Kim1,2, Genichiro Ishii1, Koichi Goto2, Kanji Nagai2, Koji Tsuta1, Satoshi Shiono1,2, Junichi Nitadori1,2, Testuro Kodama3, Yutaka Nishiwaki2 and Atsushi Ochiai1

1 Pathology Division, National Cancer Center Research Institute East, Chiba, Japan; 2 Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan; 3 Internal Medicine and Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Gefitinib (IRESSA; AstraZeneca, Osaka, Japan) shows excellent antitumor activity against advanced non–small-cell lung cancer, especially for the treatment of adenocarcinoma. However, the predictive factors for the response to gefitinib are still controversial. The aim of this study was to identify the clinicopathological and immunohistochemical features that are favorable to the use of gefitinib in adenocarcinoma patients.

Experimental Design: Between June 2002 and October 2003, 36 adenocarcinoma patients who experienced a relapse after surgical resection were treated with gefitinib at our hospital. The histologic patterns of the tumors were divided into four distinctive subtypes according to the revised World Health Organization histologic classification, and the dominant histologic subtype for the maximum cut surface of each resected specimen was documented. Association between the response to gefitinib and the clinicopathological features or immunohistochemical expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, or c-erbB-2 were then investigated.

Results: A significant association between the response to gefitinib and dominant papillary subtype findings was observed (P = 0.0021); the survival time of papillary subtype patients was also significantly prolonged compared with that of non-papillary subtype patients (P = 0.03). No other clinicopathological features or the expression of EGFR, phosphorylated EGFR, or c-erbB-2 were associated with the response to gefitinib.

Conclusions: The results of the present study indicate that dominant papillary subtype findings of lung adenocarcinomas can be an important predictor of the response to gefitinib. Thus, this type of adenocarcinoma might be susceptible to postoperative adjuvant treatment with gefitinib.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Lung cancer is the leading cause of cancer deaths in many countries, and the global incidence is rising at a rate of 0.5% per annum (1 , 2) . Platinum-based combination chemotherapy has been shown to improve survival and quality-of-life in patients with advanced non–small-cell lung cancer (NSCLC; ref 3 and 4 ), which accounts for approximately 80% of all lung cancers. New chemotherapeutic agents, like gemcitabine, vinorelbine, docetaxel, paclitaxel, and irinotecan, were developed in the 1990s. However, chemotherapy for advanced NSCLC has been of limited benefit, with response rates of approximately 30% and a median survival period of about 8 months, and it seems to have reached a plateau (1 , 5 , 6) . It is clear that additional treatment strategies are necessary.

Epidermal growth factor receptor (EGFR) has been shown to play an important role in the growth of many solid tumors and is overexpressed in approximately 40 to 80% of NSCLCs (7, 8, 9) . Furthermore, the overexpression of EGFR has been associated with a poor prognosis in several studies on lung cancer (10 , 11) . EGFR activation occurs when ligands, such as epidermal growth factor, transforming growth factor-{alpha}, or amphiregulin, bind to its extracellular domain, resulting in cell proliferation, angiogenesis, metastasis, and antiapoptosis (8 , 9) . Gefitinib (IRESSA; AstraZeneca, Osaka, Japan) is an orally active, selective EGFR tyrosine kinase inhibitor that blocks downstream of the EGFR signal transduction pathway (12) . In this context, gefitinib has a quite different profile from chemotherapeutic agents that have ever been used.

After phase I studies, two multicenter, randomized, double-blind phase II studies (IDEAL1, ref. 13 ; IDEAL2, ref. 14 ) were carried out to evaluate the tolerability and efficacy of gefitinib in patients with advanced NSCLC who had been treated previously with platinum-based combination chemotherapy. In total, 426 patients were enrolled in the two studies, and all of the patients had been treated previously with platinum-based combination chemotherapy. In both studies, the administration of two different gefitinib dosages (250 mg/day and 500 mg/day) were compared. No significant differences in efficacy were seen between the two dosages, but the 250 mg/day treatment was better tolerated than the 500 mg/day treatment in both studies. For the 250 mg/day gefitinib arms, the response rates were 18.4% and 12.0% in IDEAL1 and IDEAL2, respectively.

The results of IDEAL1 showed that gefitinib was significantly more effective for the treatment of adenocarcinomas than for other histologies (odds ratio, 3.45) and was also more effective in females than in males (odds ratio, 2.65). These findings were unexpected, given the mechanism of the drug, because squamous cell carcinomas are known to overexpress EGFR, the target of gefitinib, to a greater degree than adenocarcinomas. On the other hand, gefitinib-induced severe acute interstitial pneumonia resulting in a high mortality rate is a serious social problem in Japan (15) . Although the precise mechanism of gefitinib’s action is not yet completely understood, clinically it is more important to identify favorable characteristics in the treatment with gefitinib.

Gefitinib has been confirmed to be significantly effective for the treatment of adenocarcinomas, and some investigators have reported that gefitinib is especially effective in adenocarcinomas with bronchiolo-alveolar features (16 , 17) . To the best of our knowledge, however, these studies only examined biopsy specimens, and no studies examining surgical specimens have been done. Lung cancer is generally characterized by histologic heterogeneity; thus, studies examining histologic features should be done using surgically resected specimens.

In this study, we investigated the clinicopathological and immunohistochemical features of surgically resected adenocarcinoma specimens from patients who were subsequently treated with gefitinib after relapse to identify any characteristics that were associated with a favorable response to gefitinib.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients.
Between June 2002 and October 2003, 253 consecutive patients were treated with a 250 mg daily dosage of gefitinib at our hospital. To select fully treated patients, we defined assessable patients as follows. Response evaluation using chest computed tomography was done after receiving gefitinib at least for > 4 weeks. Among 253 patients, 222 satisfied these criteria. Of these 222 patients, 48 patients (36 patients with adenocarcinomas, 7 patients with squamous cell carcinomas, 3 patients with large cell carcinomas, 1 patient with adenosquamous carcinoma, and 1 patient with pleomorphic carcinoma) had previously undergone a lung resection for primary NSCLC at our hospital. In this study, we analyzed 36 surgically resected adenocarcinoma specimens. At the time of analysis, the mean gefitinib treatment period of these 36 patients was 172 days (range, 29–542 days).

Pathological Studies.
All surgical specimens were fixed with 10% formalin or absolute methanol and embedded in paraffin. The tumors were cut at approximately 5-mm intervals, and serial 4-µm sections were stained with H&E, Alcian blue-periodic acid Schiff method to visualize cytoplasmic mucin production, or Verhoeff van-Gieson method (18) to visualize elastic fibers. Lymphatic permeation and pulmonary metastases were evaluated on sections stained with H&E. Vascular invasion and pleural invasion were evaluated with the Verhoeff van-Gieson method. Three observers (Y. K., G. I., and K. T.) who were unaware of the clinical data independently reviewed all pathologic slides. The histologic diagnoses were based on the revised World Health Organization histologic classification (19) . In addition, the histologic subtypes and percentage of each subtype present in the tumor were evaluated with the maximum cut surface of the tumor. The histologic patterns were divided into four distinctive subtypes: bronchioloalveolar carcinoma (BAC), acinar subtype, papillary subtype, and solid adenocarcinoma with mucin. The dominant subtype of each tumor was then documented. Tumor size was measured as the maximal diameter on the cut section of the lung. The pathologic stage was determined according to the classification of the Union Internationale Contre le Cancer (20) .

Immunohistochemistry.
Tissue blocks were cut into 4-µm sections and mounted on silane-coated slides (Matsunami, Tokyo, Japan). The slides were then deparaffinized in xylene, dehydrated in a graded alcohol series, and blocked for endogenous peroxidase with 3% H2O2 in absolute methanol. After microwave pretreatment in citrate buffer (pH 6.0) at 95°C for 20 minutes, immunostaining was done at 4°C overnight with a mouse monoclonal antihuman EGFR (Novocastra, Newcastle, United Kingdom; ref. 21 ) at a dilution of 1:10, a mouse monoclonal antihuman phosphorylated EGFR (provided by Kyowahakko, Tokyo, Japan) that recognizes Try-1173 of the activated EGFR at a dilution of 1:10. As for the use of the antihuman phosphorylated EGFP (p-EGFR), a synthetic peptide (CGSTENAEpYLRVAPQSS), the amino acid sequence of which corresponds to COOH-terminal region of human EGFR, was used as an immunogen to generate a monoclonal antibody specific for the tyrosine-phosphorylated EGFR molecule. Obtained monoclonal antibody (KM2911) was further characterized by ELISA, Western blot assay, and immunohistochemical staining to verify the specificity and sensitivity. Furthermore, we compared the immunostaining of KM2911 with that of another monoclonal antibody against tyrosine-phosphorylated EGFR (MAB3052, Chemicon International, Inc., Temecula, CA) and confirmed the same specificity and sensitivity. The tissues were then exposed to DAKO EnVision+ (DAKO, Glostrup, Denmark) at room temperature for 30 minutes. Staining was visualized by exposure to 3,3'-diaminobenzidine for 3 to 5 minutes. For c-erbB-2, mouse monoclonal antihuman c-erbB-2 (Ventana, Frankfurt, Germany) and the NX/EX automatic stainer (Ventana) were used (22) As positive controls, lung adenocarcinoma specimen, which had been surgically resected at our hospital and had been determined previously to be strongly positive, was used for the EGFR and p-EGFR experiments. Breast cancer specimen, also surgically resected at our hospital and known to be strongly positive, was used for the c-erbB-2 experiment. Negative controls for each antibody were done with nonimmune serum instead of the primary antibodies. The expression of each receptor was scored as follows: – = no discernible staining, or <10% of cells stained; 1+ = >10% of cytoplasmic staining, or plasma membrane staining with weak intensity; 2+ = >10% of plasma membrane staining with moderate intensity; and 3+ = >10% of plasma membrane staining with strong intensity. Staining of 2+ and 3+ were evaluated as positive. As for EGFR and p-EGFR, no universal evaluation criteria exist at present; therefore, we applied the same criteria as c-erbB-2. Although this evaluation criteria basically followed HercepTest (23) , we added some modification to evaluate cytoplasmic staining.

Statistical Analysis.
All statistical analyses were done with the statistical program StatView, version 5.0 (Abacus Concepts, Berkley, CA). The significance of the relationships between individual clinicopathologic factors; the expression of EGFR, p-EGFR, and c-erbB-2; and a univariate analysis with the Fisher exact probability test was used to evaluate the response to gefitinib. A multivariate regression analysis was conducted according to the Cox proportional hazard model. Kaplan-Meier method was used to calculate survival rates, and a log-rank test was used to evaluate the statistical significance of any differences. A P value of less than 0.05 was considered significant.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Clinical Characteristics.
The patient characteristics are shown in Table 1Citation . All clinical data were retrieved from medical records. The mean age of the patients was 70 years (range, 43–82 years). Seventeen patients were male and 19 were female. The Eastern Cooperative Oncology Group performance status was 0 for 7 patients, 1 for 25 patients, and 2 for 4 patients. Sixteen patients were current or ex-smokers. Nineteen patients had been treated previously with chemotherapeutic agents for postoperative recurrences. The Response Evaluation Criteria in Solid Tumors (24) was used to evaluate the response of the patients. Seventeen patients experienced a partial response (PR) to gefitinib, 16 patients had a stable disease (SD), and 3 patients had a progressive disease (PD); the overall response (OR) rate was 47%. No clinical differences were observed between the responders and the non-responders (Table 2)Citation . Mean duration of response was 258 days; however, 11 of 17 responded patients were continuing gefitinib at the time of analysis.


View this table:
[in this window]
[in a new window]

  		Table 1 Patient characteristics (N = 36)

 

View this table:
[in this window]
[in a new window]

  		Table 2 Univariate analysis of clinicopathological factors (N = 36)

 
Pathologic Findings of Surgical Specimens.
The details of the pathologic findings for the surgical specimens are summarized in Table 3Citation . The pathologic stage was IA in 3 cases, IB in 6 cases, IIA in 0 cases, IIB in 3 cases, IIIA in 11 cases, IIIB in 11 cases, and IV in 1 case. The stage IV disease was caused by pulmonary metastasis to another lobe. The pathologic stage could not be determined in one case, because only a partial resection had been done. All but 3 specimens were adenocarcinomas of mixed subtype. The dominant histologic subtype was BAC in 7 cases, acinar subtype in 5 cases, papillary subtype in 17 cases, and solid adenocarcinoma with mucin in 7 cases. Both a dominant papillary subtype (P = 0.0021) and the presence of pleural invasion (P = 0.0489) were significantly associated with the response to gefitinib when examined with a univariate analysis (Table 2)Citation , but a multivariate analysis revealed that a dominant papillary subtype was the only significant factor (Table 4)Citation . In addition, the survival period of the dominant papillary subtype patients was longer than that of the non-papillary subtype patients (Fig. 1)Citation . The representative histologic features of the papillary subtype are shown in Fig. 2Citation .


View this table:
[in this window]
[in a new window]

  		Table 3 Pathological findings of adenocarcinoma cases (N = 36)

 

View this table:
[in this window]
[in a new window]

  		Table 4 Multivariate analysis

 


View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Survival curves of the adenocarcinoma patients treated with gefitinib.

 


View larger version (149K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Representative case of papillary adenocarcinoma (HEx 100). Tumor cells are growing with their own fibrovascular stroma and displaying complicated secondary and tertiary papillary branches. Abbreviation: HE, hematoxylin and eosin.

 
Immunohistochemistry.
The immunohistochemical evaluation was done according to the scoring system described in Patients and Methods. Immunohistochemistry was not done in one patient, because a tissue block was not available. Nine patients (28%) were positive for EGFR, and 14 (40%) were positive for p-EGFR. None of the patients were positive for c-erbB-2. No substantial association was observed between the immunohistochemical expression of each receptor and the response to gefitinib. The results of immunohistochemistry are summarized in Table 5Citation .


View this table:
[in this window]
[in a new window]

  		Table 5 Results of immunostaining (N = 35)

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Adenocarcinomas were known to be significantly sensitive to the treatment with gefitinib, despite their lower expression rates of EGFR compared with squamous cell carcinomas (13) . Some investigators have reported that gefitinib is particularly effective especially in BAC (16 , 17) , and clinical trials targeting BAC are now under way (25) . In fact, as Hirsch et al. (8) reported, a high expression level of both EGFR and c-erbB-2 was seen in the BAC in a preclinical study. However, the association between the overexpression of EGFR or c-erbB-2 and the sensitivity to gefitinib is still controversial (26, 27, 28) , and no data supporting an association has been obtained in clinical studies (29) . Moreover, none of the previous studies examined surgical specimens, although BAC cannot be diagnosed with small biopsy specimens (19) . In the present study, we investigated the clinicopathological and immunohistochemical features of surgically resected specimens from adenocarcinoma patients who were treated with gefitinib for postoperative recurrences. The surgical specimens were used to determine the dominance of the histologic subtypes according to the revised World Health Organization classification and to precisely evaluate the expressions of EGFR, p-EGFR, and c-erbB-2.

Clinical factors, including age, gender, performance status, smoking history, previous chemotherapy, and recurrence site, were not associated with the response to gefitinib in this study. The immunohistochemical expression profiles of EGFR, p-EGFR, and c-erbB-2 were also not associated with the response. However, both the dominant histologic subtype and the presence of pleural invasion differed significantly between responders and non-responders according to a univariate analysis, whereas a multivariate analysis revealed that only the dominant histologic subtype was a significant factor. In other words, a dominant papillary subtype was the feature that most favored a response to gefitinib, and the survival period of patients with this feature was significantly longer than that of patients with non-papillary subtypes.

The finding that gefitinib is more effective in papillary subtype lesion is of great interest. Drug delivery might be more effective in this histologic subtype, because cancer cells with a papillary structure usually line the fibrovascular stroma. In an in vitro and in vivo study, Hirata et al. (30) showed that the antitumor effect of gefitinib was partly mediated by the inhibition of tumor angiogenesis through direct effects on microvascular endothelial cells that express EGFR. In the papillary subtype, this direct effect on microvascular endothelial cells might be more efficient than in other subtypes.

The results of the present immunohistochemical study suggest that EGFR expression is not a useful predictor of the response to gefitinib. Recently, Paez et al. (31) and Lynch et al. (32) originally showed that EGFR mutations may predict sensitivity to gefitinib. These epoch-making studies arouse an interest about association of EGFR mutations with histologic subtypes.

In the present study, 9 patients (28%) were positive for EGFR and 14 (40%) were positive for p-EGFR. It seems somewhat strange that the positive rate of p-EGFR surpassed that of EGFR; however, we consider that it is simply because the p-EGFR antibody was more sensitive than the EGFR antibody.

The response rate of our study was high even for adenocarcinoma patients; however, patients were not selected at a point of administration of gefitinib for the most likely respond and patient’s selection in the present study strictly followed the definition described in the Patients and Methods section. The relatively high proportion of female (53%) and never-smoker (56%) might lead to this result.

A micropapillary pattern (MPP) of lung adenocarcinoma, which was not included in the revised World Health Organization histologic classification, was first described by Silver and Askin (33) . Lung adenocarcinomas characterized by MPP are thought to be more likely to metastasize and have a poor prognosis (34 , 35) . Most MPP-positive adenocarcinoma cases were included in the papillary subtype in the present study. Miler et al. (16) reported that a never-smoker status was a significant predictor of the response to gefitinib, whereas Wu et al. (36) reported that all of their patients who achieved a complete response with gefitinib had bilateral diffuse small pulmonary metastases. Both a never-smoker status and diffuse pulmonary metastases are frequently observed in MPP-positive adenocarcinoma (35) . These reports, combined with the results of the present study, suggest that gefitinib might be effective against MPP-positive adenocarcinoma. In fact, MPP-positive adenocarcinomas (12 cases) were more sensitive to gefitinib than MPP-negative lesions (24 cases) in the present study (P = 0.0328).

In conclusion, the results of the present study indicate that a dominant papillary adenocarcinoma subtype can be an important predictor of the response to gefitinib. Even in patients with pathologic stage IA NSCLC who undergo a complete resection, the 5-year survival rate is about 70% at best (2) . Therefore, adenocarcinoma with a dominant papillary subtype might be susceptible to postoperative adjuvant treatments with gefitinib. However, the precise mechanism of how this agent works is still obscure. Additional studies are needed to reveal the relation between the sensitivity to gefitinib and the histology of papillary subtype.


   FOOTNOTES
 
Grant support: in part by a Grant-in-Aid for Cancer Research from the Japanese Ministry of Health and Welfare and by a Grant-in-Aid for the Second Term Comprehensive 10-Year Strategy for Cancer Control that was also from the Ministry of Health and Welfare.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Atsushi Ochiai, Pathology Division, National Cancer Center Research Institute East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan, Phone: 81-4-7133-1111; Fax: 81-4-7131-4724; E-mail: aochiai{at}east.ncc.go.jp

Received 4/26/04; revised 7/12/04; accepted 7/19/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Spiro SG, Porter JC. Lung cancer–where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166:1166-1196.[Abstract/Free Full Text]
  2. Pass HI, Mitchell JB, Johnson DH, et al . Lung cancer: principles and practice 2nd edition. 2000 Lippincott Williams & Wilkins Philadelphia
  3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.[Abstract/Free Full Text]
  4. Souquet PJ, Chauvin F, Boissel JP, et al Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.[CrossRef][Medline]
  5. Schiller JH, Harrington D, Belani CP, et al Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.[Abstract/Free Full Text]
  6. Kelly K, Crowley J, Bunn PA, Jr, et al Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.[Abstract/Free Full Text]
  7. Salomon DS, Brandt R, Ciardiello F, et al Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.[Medline]
  8. Hirsch FR, Scagliotti GV, Langer CJ, et al Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41(Suppl 1):S29-S42.
  9. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.[CrossRef][Medline]
  10. Veale D, Kerr N, Gibson GJ, et al The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-165.[Medline]
  11. Volm M, Mattern J, Koomagi R. Association between nm23–H1 expression, proliferation and apoptosis in non-small cell lung carcinomas. Clin Exp Metastasis 1998;16:595-602.[CrossRef][Medline]
  12. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 2002;7(Suppl 4):31-39.
  13. Fukuoka M, Yano S, Giaccone G, et al Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.[Abstract/Free Full Text]
  14. Kris MG, Natale RB, Herbst RS, et al Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.[Abstract/Free Full Text]
  15. Inoue A, Saijo Y, Maemondo M, et al Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.[CrossRef][Medline]
  16. Miller VA, Kris MG, Shah N, et al Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109.[Abstract/Free Full Text]
  17. Argiris A, Mittal N, Masters G; Northwestern University, Chicago, IL; Evanston Northwestern Healthcare, Evanston, IL. Gefitinib (ZD1839) as first-line, compassionate use therapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC), abstract 2729. Available at http://www.asco.org. Proc Am Soc Clin Oncol 2003;22:679
  18. Ohar JA, Waller KS, DeMello D, et al Administration of chronic intravenous platelet-activating factor induces pulmonary arterial atrophy and hypertension in rabbits. Lab Investig 1991;65:451-458.[Medline]
  19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumours with contributions by Pathologists from 14 Countries Series: WHO. World Health Organization. International Histological Classification of Tumours 3rd edition. 1999156
  20. Sobin LH Wittekind CH eds. . International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, fifth edition 1997 John Wiley and Sons, Inc. New York
  21. Araki K, Ishii G, Yokose T, et al Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-180.[CrossRef][Medline]
  22. Latif Z, Watters AD, Dunn I, et al HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?. Eur. J Cancer 2004;40:56-63.
  23. Jacobs TW, Gown AM, Yaziji H, et al Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987.[Abstract/Free Full Text]
  24. Therasse P, Arbuck SG, Eisenhauer EA, et al New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-216.[Abstract/Free Full Text]
  25. Howard L, West WAF, Gumerlock, Pet al. zd1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): a preliminary report of SWOG S0126, abstract O-187. 10th World Conference on Lung Cancer, August 10–14, 2003, Vancouver, British Columbia, Canada. Aurora, Colorado: International Association for the Study of Lung Cancer; 2003.
  26. Suzuki T, Nakagawa T, Endo H, et al The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.[CrossRef][Medline]
  27. Moasser MM, Basso A, Averbuch SD, et al The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-7188.[Abstract/Free Full Text]
  28. Anderson NG, Ahmad T, Chan K, et al ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001;94:774-782.[CrossRef][Medline]
  29. Cappuzzo F, Gregorc V, Rossi E, et al Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-2663.[Abstract/Free Full Text]
  30. Hirata A, Ogawa S, Kometani T, et al ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560.[Abstract/Free Full Text]
  31. Paez JG, Janne PA, Lee JC, et al EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC) 2004;304:1497-1500.[Abstract/Free Full Text]
  32. Lynch TJ, Bell DW, Sordella R, et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.[Abstract/Free Full Text]
  33. Silver SA, Askin FB. True papillary carcinoma of the lung: a distinct clinicopathologic entity. Am J Surg Pathol 1997;21:43-51.[CrossRef][Medline]
  34. Amin MB, Tamboli P, Merchant SH, et al Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-364.[CrossRef][Medline]
  35. Miyoshi T, Satoh Y, Okumura S, et al Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-109.[CrossRef][Medline]
  36. Wu YL, Yang XN, Gu LJ, et al. The characteristics of patients with non-small cell lung cancer with complete response treated with ZD1839, abstract 2770. Available at http://www.asco.org. Proc Am Soc Clin Oncol 2003;22:689.



This article has been cited by other articles:


Home page
 Am J Clin PatholHome page
G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al.
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Am J Clin Pathol, April 1, 2009; 131(4): 478 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
N. Steeghs, J. W. R. Nortier, and H. Gelderblom
Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
Ann. Surg. Oncol., February 1, 2007; 14(2): 942 - 953.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Thorax, February 1, 2006; 61(2): 140 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Ishikawa, Y. Daigo, A. Takano, M. Taniwaki, T. Kato, S. Hayama, H. Murakami, Y. Takeshima, K. Inai, H. Nishimura, et al.
Increases of Amphiregulin and Transforming Growth Factor-{alpha} in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers
Cancer Res., October 15, 2005; 65(20): 9176 - 9184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, et al.
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2005; 23(28): 6829 - 6837.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, Y. H.
Right arrow Articles by Ochiai, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, Y. H.
Right arrow Articles by Ochiai, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online